Yumanity selling neurology assets and merging with Kineta
U.S. biopharma company Yumanity Therapeutics, Inc. is selling off its lead clinical-stage neurodegenerative product candidate…
U.S. biopharma company Yumanity Therapeutics, Inc. is selling off its lead clinical-stage neurodegenerative product candidate…
Johnson & Johnson became the latest company to have a failed vaccine trial against HIV…
While the EU saw rapid-fire approvals in the multiple sclerosis space last month, the innovations…
When it comes to drug discovery and development, nowadays a lot of the work is…
Last year Berlin, this year Copenhagen - No matter where in Europe, this is the…
What would a large event like BIO-Europe be without startups? They’re not only the life…
The UK-based VC Medicxi has raised a massive $300M (€268M) fund backed by Novartis and…
Blockbuster drugs are raking in billions each year in sales. Let's have a look at the top…
Johnson & Johnson is certainly counting on its recent acquisition of the European biotech success Actelion…
Actelion will be acquired by J&J for a whopping €27.9B, and its early R&D pipeline…
UPDATE (12/01/2017): J&J and Actelion have reportedly settled on a price: $260 (€245) per share,…
Curious about which technologies have attracted the most cash in biotech finance this year? Here's a…